Literature DB >> 33533300

Exercise-induced alterations in phospholipid hydrolysis, airway surfactant, and eicosanoids and their role in airway hyperresponsiveness in asthma.

Ryan C Murphy1,2, Ying Lai1,2, James D Nolin1,2, Robier A Aguillon Prada3,4, Arindam Chakrabarti3,4, Michael V Novotny3,4, Michael C Seeds5, William A Altemeier1,2, Michael H Gelb6,7, Robert Duncan Hite8, Teal S Hallstrand1,2.   

Abstract

The mechanisms responsible for driving endogenous airway hyperresponsiveness (AHR) in the form of exercise-induced bronchoconstriction (EIB) are not fully understood. We examined alterations in airway phospholipid hydrolysis, surfactant degradation, and lipid mediator release in relation to AHR severity and changes induced by exercise challenge. Paired induced sputum (n = 18) and bronchoalveolar lavage (BAL) fluid (n = 11) were obtained before and after exercise challenge in asthmatic subjects. Samples were analyzed for phospholipid structure, surfactant function, and levels of eicosanoids and secreted phospholipase A2 group 10 (sPLA2-X). A primary epithelial cell culture model was used to model effects of osmotic stress on sPLA2-X. Exercise challenge resulted in increased surfactant degradation, phospholipase activity, and eicosanoid production in sputum samples of all patients. Subjects with EIB had higher levels of surfactant degradation and phospholipase activity in BAL fluid. Higher basal sputum levels of cysteinyl leukotrienes (CysLTs) and prostaglandin D2 (PGD2) were associated with direct AHR, and both the postexercise and absolute change in CysLTs and PGD2 levels were associated with EIB severity. Surfactant function either was abnormal at baseline or became abnormal after exercise challenge. Baseline levels of sPLA2-X in sputum and the absolute change in amount of sPLA2-X with exercise were positively correlated with EIB severity. Osmotic stress ex vivo resulted in movement of water and release of sPLA2-X to the apical surface. In summary, exercise challenge promotes changes in phospholipid structure and eicosanoid release in asthma, providing two mechanisms that promote bronchoconstriction, particularly in individuals with EIB who have higher basal levels of phospholipid turnover.

Entities:  

Keywords:  airway hyperresponsiveness; asthma; eicosanoid; phospholipase A2; surfactant

Mesh:

Substances:

Year:  2021        PMID: 33533300      PMCID: PMC8174822          DOI: 10.1152/ajplung.00546.2020

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  42 in total

1.  Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999.

Authors:  R O Crapo; R Casaburi; A L Coates; P L Enright; J L Hankinson; C G Irvin; N R MacIntyre; R T McKay; J S Wanger; S D Anderson; D W Cockcroft; J E Fish; P J Sterk
Journal:  Am J Respir Crit Care Med       Date:  2000-01       Impact factor: 21.405

2.  Well-differentiated human airway epithelial cell cultures.

Authors:  M Leslie Fulcher; Sherif Gabriel; Kimberlie A Burns; James R Yankaskas; Scott H Randell
Journal:  Methods Mol Med       Date:  2005

3.  ERS technical standard on bronchial challenge testing: pathophysiology and methodology of indirect airway challenge testing.

Authors:  Teal S Hallstrand; Joerg D Leuppi; Guy Joos; Graham L Hall; Kai-Håkon Carlsen; David A Kaminsky; Allan L Coates; Donald W Cockcroft; Bruce H Culver; Zuzana Diamant; Gail M Gauvreau; Ildiko Horvath; Frans H C de Jongh; Beth L Laube; Peter J Sterk; Jack Wanger
Journal:  Eur Respir J       Date:  2018-11-15       Impact factor: 16.671

4.  Different functional aspects of the group II subfamily (Types IIA and V) and type X secretory phospholipase A(2)s in regulating arachidonic acid release and prostaglandin generation. Implications of cyclooxygenase-2 induction and phospholipid scramblase-mediated cellular membrane perturbation.

Authors:  M Murakami; T Kambe; S Shimbara; K Higashino; K Hanasaki; H Arita; M Horiguchi; M Arita; H Arai; K Inoue; I Kudo
Journal:  J Biol Chem       Date:  1999-10-29       Impact factor: 5.157

5.  Is there a unifying hypothesis for exercise-induced asthma?

Authors:  S D Anderson
Journal:  J Allergy Clin Immunol       Date:  1984-05       Impact factor: 10.793

6.  Relationship between levels of secreted phospholipase A₂ groups IIA and X in the airways and asthma severity.

Authors:  T S Hallstrand; Y Lai; Z Ni; R C Oslund; W R Henderson; M H Gelb; S E Wenzel
Journal:  Clin Exp Allergy       Date:  2011-01-24       Impact factor: 5.018

7.  Combined activities of secretory phospholipases and eosinophil lysophospholipases induce pulmonary surfactant dysfunction by phospholipid hydrolysis.

Authors:  Mark A Kwatia; Christine B Doyle; Wonwha Cho; Goran Enhorning; Steven J Ackerman
Journal:  J Allergy Clin Immunol       Date:  2007-02-23       Impact factor: 10.793

8.  Interfacial kinetic and binding properties of the complete set of human and mouse groups I, II, V, X, and XII secreted phospholipases A2.

Authors:  Alan G Singer; Farideh Ghomashchi; Catherine Le Calvez; James Bollinger; Sofiane Bezzine; Morgane Rouault; Martin Sadilek; Eric Nguyen; Michel Lazdunski; Gerard Lambeau; Michael H Gelb
Journal:  J Biol Chem       Date:  2002-09-30       Impact factor: 5.157

9.  Effectiveness of screening examinations to detect unrecognized exercise-induced bronchoconstriction.

Authors:  Teal S Hallstrand; J Randall Curtis; Thomas D Koepsell; Diane P Martin; Robert B Schoene; Sean D Sullivan; Gerald N Yorioka; Moira L Aitken
Journal:  J Pediatr       Date:  2002-09       Impact factor: 4.406

10.  KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma.

Authors:  Katherine N Cahill; Howard R Katz; Jing Cui; Juying Lai; Shamsah Kazani; Allison Crosby-Thompson; Denise Garofalo; Mario Castro; Nizar Jarjour; Emily DiMango; Serpil Erzurum; Jennifer L Trevor; Kartik Shenoy; Vernon M Chinchilli; Michael E Wechsler; Tanya M Laidlaw; Joshua A Boyce; Elliot Israel
Journal:  N Engl J Med       Date:  2017-05-18       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.